BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 37074911)

  • 1. Integrated glycoproteomic characterization of clear cell renal cell carcinoma.
    Lih TM; Cho KC; Schnaubelt M; Hu Y; Zhang H
    Cell Rep; 2023 May; 42(5):112409. PubMed ID: 37074911
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BAP1 and PBRM1 in metastatic clear cell renal cell carcinoma: tumor heterogeneity and concordance with paired primary tumor.
    Eckel-Passow JE; Serie DJ; Cheville JC; Ho TH; Kapur P; Brugarolas J; Thompson RH; Leibovich BC; Kwon ED; Joseph RW; Parker AS
    BMC Urol; 2017 Mar; 17(1):19. PubMed ID: 28327121
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Defining the human kidney N-glycome in normal and cancer tissues using MALDI imaging mass spectrometry.
    Drake RR; McDowell C; West C; David F; Powers TW; Nowling T; Bruner E; Mehta AS; Angel PM; Marlow LA; Tun HW; Copland JA
    J Mass Spectrom; 2020 Apr; 55(4):e4490. PubMed ID: 31860772
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Proteomic identification of angiomotin by ProteomeLab PF-2D and correlation with clinical outcome in human clear cell renal cell carcinoma.
    Yang J; Liu P; Tian M; Li Y; Chen W; Li X
    Int J Oncol; 2013 Jun; 42(6):2078-86. PubMed ID: 23588948
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification and validation of novel prognostic markers in Renal Cell Carcinoma.
    Rabjerg M
    Dan Med J; 2017 Oct; 64(10):. PubMed ID: 28975890
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adverse outcomes in clear cell renal cell carcinoma with mutations of 3p21 epigenetic regulators BAP1 and SETD2: a report by MSKCC and the KIRC TCGA research network.
    Hakimi AA; Ostrovnaya I; Reva B; Schultz N; Chen YB; Gonen M; Liu H; Takeda S; Voss MH; Tickoo SK; Reuter VE; Russo P; Cheng EH; Sander C; Motzer RJ; Hsieh JJ;
    Clin Cancer Res; 2013 Jun; 19(12):3259-67. PubMed ID: 23620406
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An integrative genomics approach for identifying novel functional consequences of PBRM1 truncated mutations in clear cell renal cell carcinoma (ccRCC).
    Wang Y; Guo X; Bray MJ; Ding Z; Zhao Z
    BMC Genomics; 2016 Aug; 17 Suppl 7(Suppl 7):515. PubMed ID: 27556922
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Histology-guided proteomic analysis to investigate the molecular profiles of clear cell Renal Cell Carcinoma grades.
    Stella M; Chinello C; Cazzaniga A; Smith A; Galli M; Piga I; Grasso A; Grasso M; Del Puppo M; Varallo M; Bovo G; Magni F
    J Proteomics; 2019 Jan; 191():38-47. PubMed ID: 29698802
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-dimensional Cytometry (ExCYT) and Mass Spectrometry of Myeloid Infiltrate in Clinically Localized Clear Cell Renal Cell Carcinoma Identifies Novel Potential Myeloid Targets for Immunotherapy.
    Theodros D; Murter BM; Sidhom JW; Nirschl TR; Clark DJ; Chen L; Tam AJ; Blosser RL; Schwen ZR; Johnson MH; Pierorazio PM; Zhang H; Ganguly S; Pardoll DM; Zarif JC
    Mol Cell Proteomics; 2020 Nov; 19(11):1850-1859. PubMed ID: 32737216
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Identification of Zinc-Finger Protein 433 as a Possible Prognostic Biomarker for Clear-Cell Renal Cell Carcinoma.
    Heyliger SO; Soliman KFA; Saulsbury MD; Reams RR
    Biomolecules; 2021 Aug; 11(8):. PubMed ID: 34439859
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Loss of BAP1 expression in metastatic tumor tissue is an event of poor prognosis in patients with metastatic clear cell renal cell carcinoma.
    da Costa WH; Fares AF; Bezerra SM; Morini MA; de Toledo Benigno LA; Clavijo DA; Fornazieri L; Rocha MM; da Cunha IW; de Cassio Zequi S
    Urol Oncol; 2019 Jan; 37(1):78-85. PubMed ID: 30446457
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Loss of PBRM1 expression is associated with renal cell carcinoma progression.
    Pawłowski R; Mühl SM; Sulser T; Krek W; Moch H; Schraml P
    Int J Cancer; 2013 Jan; 132(2):E11-7. PubMed ID: 22949125
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Proteomic analysis reveals differentially secreted proteins in the urine from patients with clear cell renal cell carcinoma.
    Sandim V; Pereira Dde A; Kalume DE; Oliveira-Carvalho AL; Ornellas AA; Soares MR; Alves G; Zingali RB
    Urol Oncol; 2016 Jan; 34(1):5.e11-25. PubMed ID: 26420021
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clusterin glycopeptide variant characterization reveals significant site-specific glycan changes in the plasma of clear cell renal cell carcinoma.
    Gbormittah FO; Bones J; Hincapie M; Tousi F; Hancock WS; Iliopoulos O
    J Proteome Res; 2015 Jun; 14(6):2425-36. PubMed ID: 25855029
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proteotranscriptomic Analysis Reveals Stage Specific Changes in the Molecular Landscape of Clear-Cell Renal Cell Carcinoma.
    Neely BA; Wilkins CE; Marlow LA; Malyarenko D; Kim Y; Ignatchenko A; Sasinowska H; Sasinowski M; Nyalwidhe JO; Kislinger T; Copland JA; Drake RR
    PLoS One; 2016; 11(4):e0154074. PubMed ID: 27128972
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of miRNA-21 and miRNA-221 in clear cell renal cell carcinoma (ccRCC) and their possible role in the development of ccRCC.
    Szabó Z; Szegedi K; Gombos K; Mahua C; Flaskó T; Harda K; Halmos G
    Urol Oncol; 2016 Dec; 34(12):533.e21-533.e27. PubMed ID: 27427222
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The SWI/SNF Protein PBRM1 Restrains VHL-Loss-Driven Clear Cell Renal Cell Carcinoma.
    Nargund AM; Pham CG; Dong Y; Wang PI; Osmangeyoglu HU; Xie Y; Aras O; Han S; Oyama T; Takeda S; Ray CE; Dong Z; Berge M; Hakimi AA; Monette S; Lekaye CL; Koutcher JA; Leslie CS; Creighton CJ; Weinhold N; Lee W; Tickoo SK; Wang Z; Cheng EH; Hsieh JJ
    Cell Rep; 2017 Mar; 18(12):2893-2906. PubMed ID: 28329682
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of long non-coding RNA transcriptome in clear-cell renal cell carcinoma by next-generation deep sequencing.
    Malouf GG; Zhang J; Yuan Y; Compérat E; Rouprêt M; Cussenot O; Chen Y; Thompson EJ; Tannir NM; Weinstein JN; Valero V; Khayat D; Spano JP; Su X
    Mol Oncol; 2015 Jan; 9(1):32-43. PubMed ID: 25126716
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activation and function of receptor tyrosine kinases in human clear cell renal cell carcinomas.
    Zhang Q; Liu JH; Liu JL; Qi CT; Yan L; Chen Y; Yu Q
    BMC Cancer; 2019 Nov; 19(1):1044. PubMed ID: 31690270
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SIRT5-mediated SDHA desuccinylation promotes clear cell renal cell carcinoma tumorigenesis.
    Ma Y; Qi Y; Wang L; Zheng Z; Zhang Y; Zheng J
    Free Radic Biol Med; 2019 Apr; 134():458-467. PubMed ID: 30703481
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.